GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (FRA:IDP) » Definitions » Cyclically Adjusted Revenue per Share

Biogen (FRA:IDP) Cyclically Adjusted Revenue per Share : €70.46 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Biogen Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biogen's adjusted revenue per share for the three months ended in Mar. 2024 was €14.443. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €70.46 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biogen's average Cyclically Adjusted Revenue Growth Rate was 6.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 17.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biogen was 53.80% per year. The lowest was 12.20% per year. And the median was 21.50% per year.

As of today (2024-05-20), Biogen's current stock price is €210.00. Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €70.46. Biogen's Cyclically Adjusted PS Ratio of today is 2.98.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 22.51. The lowest was 2.55. And the median was 8.22.


Biogen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Revenue per Share Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.44 42.92 55.60 64.30 67.58

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.90 66.67 70.09 67.58 70.46

Competitive Comparison of Biogen's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.



Biogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=14.443/131.7762*131.7762
=14.443

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 7.507 100.560 9.837
201409 8.224 100.428 10.791
201412 9.057 99.070 12.047
201503 10.020 99.621 13.254
201506 9.797 100.684 12.822
201509 10.641 100.392 13.968
201512 11.810 99.792 15.595
201603 11.166 100.470 14.645
201606 11.740 101.688 15.214
201609 12.004 101.861 15.529
201612 12.547 101.863 16.232
201703 12.172 102.862 15.593
201706 12.911 103.349 16.462
201709 12.192 104.136 15.428
201712 13.175 104.011 16.692
201803 11.995 105.290 15.012
201806 13.860 106.317 17.179
201809 14.597 106.507 18.060
201812 15.483 105.998 19.248
201903 15.678 107.251 19.263
201906 16.811 108.070 20.499
201909 17.746 108.329 21.587
201912 18.552 108.420 22.549
202003 18.478 108.902 22.359
202006 20.319 108.767 24.617
202009 18.234 109.815 21.881
202012 15.216 109.897 18.245
202103 14.859 111.754 17.521
202106 15.345 114.631 17.640
202109 15.895 115.734 18.098
202112 16.403 117.630 18.376
202203 15.575 121.301 16.920
202206 16.753 125.017 17.659
202209 17.497 125.227 18.412
202212 16.517 125.222 17.382
202303 15.843 127.348 16.394
202306 15.580 128.729 15.949
202309 16.374 129.860 16.616
202312 14.998 129.419 15.271
202403 14.443 131.776 14.443

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biogen  (FRA:IDP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=210.00/70.46
=2.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 22.51. The lowest was 2.55. And the median was 8.22.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biogen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (FRA:IDP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (FRA:IDP) » Definitions » Cyclically Adjusted Revenue per Share
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (FRA:IDP) Headlines

No Headlines